Articles tagged "Immunosuppression"

2018 American Transplant Congress
Impact of Single Nucleotide Polymorphisms on P450 Oxidoreductase and Peroxisome Proliferator-Activated Receptor alpha on Tacrolimus Pharmacokinetics in Renal Transplant Recipients
Z. Wang, Z. Han, J. Tao, H. Chen, S. Li, R. Tan, M. Gu.
Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
The P450 oxidoreductase (POR) and peroxisome proliferator-activated receptor alpha (PPARA) genes have been reported to be associated with the activity of cytochrome P450 enzymes in…
2018 American Transplant Congress
Tacrolimus Metabolism in Subjects with Potentially Absent CYP3A Activity
A. Scheibner,¹ R. Remmel,² D. Schladt,³ W. Oetting,¹ W. Guan,⁴ B. Wu,⁴ C. Door,⁵ A. Israni,⁵ P. Jacobson.¹
¹Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN; ²Medicinal Chemistry, University of Minnesota, Minneapolis, MN; ³Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minneapolis, MN; ⁴Biostatistics, University of Minnesota, Minneapolis, MN; ⁵Department of Medicine, Hennepin County Medical Center, Minneapolis, MN.
Purpose: Tacrolimus (TAC) is a well-known cytochrome P450 (CYP) 3A4 and 3A5 substrate. Common single nucleotide polymorphisms (SNPs) in these genes are significantly related to…
2018 American Transplant Congress
Decreased Clinical Significance of Isoagglutinin Titer with the Current Desensitization Protocol in ABO-Incompatible Kidney Transplantation
C. Baek, H. Kim, W. Yang, D. Han, S-.K. Park.
Department of Internal Medicine, Division of Nephrology, Asan Medical Center, Seoul, Republic of Korea; Department of Surgery, Asan Medical Center, Seoul, Republic of Korea.
ABO-incompatible (ABOi) kidney transplantation (KT) has become a routine procedure with graft survival rates comparable to those of ABO-compatible KT. However, the clinical significance of…
2018 American Transplant Congress
Evolutive Analysis of a 20-Year Pancreas Transplant Program
M. Perosa,¹ J. Branez,¹ L. Mota,¹ H. Noujaim,¹ B. Zeballos,¹ L. Ianhez,¹ L. Alvim,¹ D. Machado,¹ C. Watanabe,¹ F. Sergi,¹ M. Paredes,¹ T. Genzini-Miranda,² A. Silvestre,³ G. Martinho,⁴ T. Genzini.¹
¹Abdominal Organ Transplantation, Leforte Hospital, Sao Paulo, Brazil; ²Medical School, PUC Sorocaba, Sorocaba, Sao Paulo, Brazil; ³Medical School, Sao Camilo, Sao Paulo, Brazil; ⁴Medical School, Ciências Médicas Santa Casa, Sao Paulo, Brazil.
There is a worldwide trend towards a reduction in the annual number of pancreas transplants (PT). In Brazil, only two centers have performed more than…
2018 American Transplant Congress
Immunosuppression and the Risk of Dementia among Older Kidney Transplant Recipients
M. McAdams DeMarco,¹ C. Haugen,¹ S. Bae,¹ K. Lentine,² D. Segev.¹
¹JHU, Baltimore; ²SLU, St. Louis.
Background: Older recipients have a high burden of dementia after kidney transplantation (KT). Factors contributing to post-KT dementia may include long-standing kidney disease, comorbid vascular…
2018 American Transplant Congress
Impact of Once-Daily Tacrolimus on Adherence in Stable Adolescent and Young Adult Renal Transplant Recipients
M. Moss,¹ J. Goebel,² M. Bock.²
¹Pharmacy, Children's Hospital Colorado, Aurora, CO; ²Pediatric Nephrology, Children's Hospital Colorado, Aurora, CO.
Medication non-adherence is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs), especially adolescents and young adults (AYA). Number of medication…
2018 American Transplant Congress
Late Conversion from Calcineurin Inhibitors to Belatacept is Associated with a Sustained Improvement in Kidney Allograft Function
S. Sethi, J. Choi, A. Vo, R. Najjar, A. Peng, S. Jordan, E. Huang.
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Belatacept was shown to have longer kidney graft survival and higher eGFR at 7 years than a calcineurin inhibitor (CNI)-based regimen in the BENEFIT…
2018 American Transplant Congress
Cognition after Belatacept Conversion
C. Ogbejesi, E. Cohen, K. Belfield, W. Asch.
Yale University, New Haven, CT.
Intro: Kidney Transplant Recipients (KTRs) taking calcineurin inhibitors (CNIs) can experience varying drug toxicities. Less well studied compared to the metabolic consequences, many patients report…
2018 American Transplant Congress
Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study
Y. Kim,¹ Y. Chiang,² S. Kim,³ M. Kim,⁴ S. Park,⁵ S. Wu,⁶ K. Horita,⁷ Y. Nakashima,⁷ H. Jiang,⁸ D. Han.¹
¹Asan Medical Center, Seoul, Korea; ²Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan; ³Samsung Medical Center, Seoul, Korea; ⁴Severance Hospital, Seoul, Korea; ⁵Dongsan Medical Center, Daegu, Korea; ⁶Tri-Service General Hospital, Taipei City, Taiwan; ⁷Astellas Pharma, Inc., Tokyo, Japan; ⁸Astellas Pharma, Inc., Maao, Singapore.
A multicenter, randomized, open-label, parallel-group, pilot, 52-wk study in Asian countries that assessed renal function, efficacy, and safety of low vs standard-dose prolonged-release tacrolimus (PRT)…
2018 American Transplant Congress
Regulation of NK Cell Cytotoxicity by TEC Expression of Clr Proteins in Kidney Ischemia Reperfusion Injury (IRI)
B. Fuhrmann,^1,5 D. Lian,⁵ Z. Yin,⁵ S. Ma,^4,5 J. Arp,⁵ Z. Zhang,^2,3,4,5 A. Jevnikar.^1,3,4,5
¹Microbiology and Immunology, Western University, London, Canada; ²Pathology, Western University, London, Canada; ³Medicine, Western University, London, Canada; ⁴Multi-Organ Transplant Program, London Health Sciences Centre, London, Canada; ⁵Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, Canada.
Background: Kidney tubular epithelial cells (TEC) may negatively regulate NK cell activation and cytotoxic capacity by surface expression of a novel class of C-type lectin-related…